|
Daily Medical Update
Meningitis
Saturday, June 27, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Lancet. Infectious diseases (2025) - Practice Guideline
Key Findings
- Tuberculous meningitis was identified as causing death or disability in around 50% of affected patients.
- The guideline consolidates recommendations intended to reduce mortality and disability across diagnosis, anti-tuberculosis chemotherapy, adjunctive anti-inflammatory therapy, and neurocritical or neurosurgical care.
📋 Practice Implication: Clinicians managing suspected or confirmed tuberculous meningitis can use this guideline as a common baseline pathway, especially when local protocols are inconsistent or outdated.
|
Journal of infection in developing countries (2026) - Network Meta-Analysis
Key Findings
- Across 29 RCTs with 4,640 patients, adjunctive prednisone was associated with lower tuberculous meningitis mortality versus standard treatment alone (OR 0.26, 95% CrI 0.07-0.78).
- Prednisolone increased neurological events (OR 5.98, 95% CrI 2.03-20.7), while standard-dose rifampicin was associated with fewer neurological events (OR 0.25, 95% CrI 0.06-0.78).
📋 Practice Implication: When selecting adjunctive therapy for tuberculous meningitis, prednisone has the strongest survival signal here, but steroid choice and accompanying regimen details should be weighed against neurological and other adverse-event tradeoffs.
|
The Lancet. Microbe (2026) - Meta-Analysis
Key Findings
- For Streptococcus pneumoniae meningitis, global resistance was 27.4% for benzylpenicillin and 8.8% for third-generation cephalosporins, with benzylpenicillin resistance increasing over time in LMICs.
- For Neisseria meningitidis, global benzylpenicillin resistance was 24.7% and increased over time, while 51.2% of Haemophilus influenzae isolates were ampicillin resistant globally.
📋 Practice Implication: Empiric meningitis regimens should be checked against current regional susceptibility data rather than assuming historic penicillin or ampicillin reliability, particularly in high-burden LMIC settings.
|
BMC medicine (2026) - Meta-Analysis
Key Findings
- In adults, pooled sequelae prevalence was 24.8% at discharge and rose to 41.5% within 3 months after discharge; hearing loss was the most frequently reported deficit.
- In children, pooled sequelae prevalence was 28.9% at discharge and 38.2% beyond 3 months after discharge, showing that substantial morbidity is still detected well after hospitalization.
📋 Practice Implication: A normal discharge exam should not end follow-up after meningitis; scheduled post-discharge review for hearing, focal deficits, seizures, and cognitive outcomes is likely to detect otherwise missed morbidity.
|
Indian pediatrics (2025) - Meta-Analysis
Key Findings
- At a cerebrospinal fluid procalcitonin cutoff of 0.20 ng/mL, pooled sensitivity was 77.1% and specificity was 68.9% in infants younger than 90 days.
- At a cutoff of 0.33 ng/mL, pooled sensitivity was 75.8% and specificity was 75.1%, but the certainty of evidence remained very low at both thresholds.
📋 Practice Implication: CSF procalcitonin may be a supporting marker in young infants, but these data do not justify using it as a stand-alone rule-in or rule-out test for meningitis.
|
|
💡
Summary
Recent meningitis evidence is led by tuberculous meningitis, with a new international practice guideline and comparative treatment data supporting selective corticosteroid use while clarifying regimen-specific harms. Across broader meningitis care, updated resistance estimates in major bacterial pathogens and high rates of post-discharge sequelae argue for locally informed empiric therapy and structured follow-up. Diagnostic innovation remains limited, as cerebrospinal fluid procalcitonin in infants showed only moderate accuracy with very low-certainty evidence.
|
|